Xytis gets $7.5M to work on central nervous system disorders
Xytis, a privately-held biotech company based in both the U.S. (Irvine, CA) and Europe (London, England and Nyon, Switzerland) has raised a new round of series B funding. The company specializes in making treatments for patients with central nervous system (CNS) disorders.
The $7.5 million round… Continue Reading
Life-science briefing: Friday, April 11, 2008
TODAY’S HEADLINES:
Stent maker IDev Tech raises $25M (VentureWire)
Xytis gets $15M for brain-injury drugs (VentureWire)
Diagnostic maker Iris Biotech plans to go public, launch breast-cancer test (Edgar)
RiverVest Venture Partners raises $75M life-science fund (release)
Concentric Medical names Maria Sainz CEO (release)
[Note: I’m a little sad to announce that this will… Continue Reading
Security company Imperva raises $20M
Imperva, a company that provides application data security, has raised $20 million in a fourth round of financing. The company’s total funding is now $54 million.
We covered the Foster City, Calif.-company back in 2006, when chief executive Shlomo Kramer (who co-founded the successful security firewall… Continue Reading